Life Science Investing Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Life Science Investing Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Life Science Investing ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Life Science Investing Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
Life Science Investing Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Life Science Investing Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Life Science Investing Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada
